# Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

> **NCT01612000** · PHASE1,PHASE2 · COMPLETED · sponsor: **Protein Sciences Corporation** · enrollment: 341 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** PanBlok
- **BIOLOGICAL:** rHA adjuvant

## Key facts

- **NCT ID:** NCT01612000
- **Lead sponsor:** Protein Sciences Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-08
- **Final completion:** 2013-12
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2015-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01612000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01612000, "Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01612000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*